As­traZeneca touts ex­tend­ed safe­ty and ef­fi­ca­cy da­ta on Fasen­ra; Vanes­sa King takes the helm at Viri­on

→ As­traZeneca $AZN has rolled out a new round of safe­ty and ef­fi­ca­cy da­ta they’ve been gath­er­ing from an ex­ten­sion study of Fasen­ra (ben­ral­izum­ab), their new drug for se­vere eosinophilic asth­ma. Re­searchers say they tracked an ex­cel­lent safe­ty pro­file at 56 weeks, adding: “74% of pa­tients with a base­line blood eosinophil count of 300 cells per μL or greater (the pri­ma­ry ef­fi­ca­cy pop­u­la­tion in the Phase III tri­als) who re­ceived FASEN­RA every eight weeks con­tin­u­ous­ly from SIROC­CO or CAL­I­MA and in­to BO­RA, were ex­ac­er­ba­tion-free in BO­RA in their sec­ond year of treat­ment and main­tained im­prove­ments in lung func­tion and asth­ma con­trol.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.